{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T01:48:07Z","timestamp":1786499287971,"version":"build-2736575974"},"reference-count":53,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C5255\/A20936"],"award-info":[{"award-number":["C5255\/A20936"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C552\/A17720"],"award-info":[{"award-number":["C552\/A17720"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C552\/A17720"],"award-info":[{"award-number":["C552\/A17720"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C552\/A17720"],"award-info":[{"award-number":["C552\/A17720"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C552\/A17720"],"award-info":[{"award-number":["C552\/A17720"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C552\/A17720"],"award-info":[{"award-number":["C552\/A17720"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000402","name":"Kay Kendall Leukaemia Fund","doi-asserted-by":"publisher","award":["KKL1050"],"award-info":[{"award-number":["KKL1050"]}],"id":[{"id":"10.13039\/501100000402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/L024012\/1"],"award-info":[{"award-number":["EP\/L024012\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0807-6","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T15:03:36Z","timestamp":1574348616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples"],"prefix":"10.1136","volume":"7","author":[{"given":"Eleanor M.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egon J.","family":"Jacobus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Dyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hena","family":"Khalique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K.","family":"Taverner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Champion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-0841","authenticated-orcid":false,"given":"Len W.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"3","key":"807_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017;31(3):311\u201325.","journal-title":"Cancer Cell"},{"issue":"7","key":"807_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"key":"807_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.exer.2012.11.012","volume":"107","author":"MC Herwig","year":"2013","unstructured":"Herwig MC, Bergstrom C, Wells JR, H\u00f6ller T, Grossniklaus HE. M2\/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles. Exp Eye Res. 2013;107:52\u20138.","journal-title":"Exp Eye Res"},{"issue":"3","key":"807_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7785\/tcrt.2012.500312","volume":"12","author":"C Lan","year":"2013","unstructured":"Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 2013;12(3):259\u201367.","journal-title":"Technol Cancer Res Treat"},{"issue":"6","key":"807_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038541","volume":"7","author":"C Page Le","year":"2012","unstructured":"Le Page C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouba I, et al. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS One. 2012;7(6):e38541.","journal-title":"PLoS One"},{"key":"807_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2407-10-112","volume":"10","author":"J Ma","year":"2010","unstructured":"Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer. 2010;10:112.","journal-title":"BMC Cancer"},{"issue":"11","key":"807_CR7","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1590\/S1807-59322011001100006","volume":"66","author":"B Zhang","year":"2011","unstructured":"Zhang B, Yao G, Zhang Y, Gao J, Yang B, Rao Z. M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo). 2011;66(11):1879\u201386.","journal-title":"Clinics (Sao Paulo)"},{"key":"807_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1757-2215-7-19","volume":"7","author":"M Zhang","year":"2014","unstructured":"Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, et al. A high M1\/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res. 2014;7:19.","journal-title":"J Ovarian Res"},{"issue":"2","key":"807_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.7314\/APJCP.2013.14.2.1003","volume":"14","author":"YL Cui","year":"2013","unstructured":"Cui YL, Li HK, Zhou HY, Zhang T, Li Q. Correlations of tumor-associated macrophage subtypes with liver metastases of colorectal cancer. Asian Pac J Cancer Prev. 2013;14(2):1003\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"807_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/sj.bjc.6603240","volume":"95","author":"SM Zeisberger","year":"2006","unstructured":"Zeisberger SM, Odermatt B, Marty C, Zehnder-Fj\u00e4llman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer. 2006;95(3):272\u201381.","journal-title":"Br J Cancer"},{"issue":"6","key":"807_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846\u201359.","journal-title":"Cancer Cell"},{"issue":"6024","key":"807_CR12","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612\u20136.","journal-title":"Science."},{"key":"807_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fonc.2018.00049","volume":"8","author":"AR Poh","year":"2018","unstructured":"Poh AR, Ernst M. Targeting macrophages in Cancer: from bench to bedside. Front Oncol. 2018;8:49.","journal-title":"Front Oncol"},{"issue":"15_suppl","key":"807_CR14","doi-asserted-by":"publisher","first-page":"11502","DOI":"10.1200\/JCO.2018.36.15_suppl.11502","volume":"36","author":"WD Tap","year":"2018","unstructured":"Tap WD, Gelderblom H, Stacchiotti S, Palmerini E, Ferrari S, Desai J, et al. Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT). J Clin Oncol. 2018;36(15_suppl):11502.","journal-title":"J Clin Oncol"},{"issue":"1","key":"807_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, R\u00fcttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):53.","journal-title":"J Immunother Cancer."},{"issue":"19","key":"807_CR16","doi-asserted-by":"publisher","first-page":"5492","DOI":"10.1158\/0008-5472.CAN-18-1367","volume":"78","author":"M Yang","year":"2018","unstructured":"Yang M, McKay D, Pollard JW, Lewis CE. Diverse functions of macrophages in different tumor microenvironments. Cancer Res. 2018;78(19):5492\u2013503.","journal-title":"Cancer Res"},{"issue":"15","key":"807_CR17","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","volume":"92","author":"M Mack","year":"1995","unstructured":"Mack M, Riethm\u00fcller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A. 1995;92(15):7021\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"807_CR18","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, et al. FDA Approval: Blinatumomab. Clin Cancer Res. 2015;21(18):4035\u20139.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"807_CR19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/cpt.651","volume":"101","author":"T Yuraszeck","year":"2017","unstructured":"Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and clinical development of Bispecific T-cell engaging antibodies for Cancer treatment. Clin Pharmacol Ther. 2017;101(5):634\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"24","key":"807_CR20","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","volume":"78","author":"JD Freedman","year":"2018","unstructured":"Freedman JD, Duffy MR, Lei-Rossmann J, Muntzer A, Scott EM, Hagel J, et al. An Oncolytic virus expressing a T-cell engager simultaneously targets Cancer and immunosuppressive stromal cells. Cancer Res. 2018;78(24):6852\u201365.","journal-title":"Cancer Res"},{"issue":"1","key":"807_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40425-019-0505-4","volume":"7","author":"J Sostoa de","year":"2019","unstructured":"de Sostoa J, Fajardo CA, Moreno R, Ramos MD, Farrera-Sal M, Alemany R. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J Immunother Cancer. 2019;7(1):19.","journal-title":"J Immunother Cancer."},{"key":"807_CR22","doi-asserted-by":"crossref","unstructured":"Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol Med. 2017:e201707567.","DOI":"10.15252\/emmm.201707567"},{"issue":"1","key":"807_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/mt.2013.240","volume":"22","author":"F Yu","year":"2014","unstructured":"Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther. 2014;22(1):102\u201311.","journal-title":"Mol Ther"},{"issue":"14","key":"807_CR24","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1158\/0008-5472.CAN-09-4672","volume":"70","author":"K Movahedi","year":"2010","unstructured":"Movahedi K, Laoui D, Gysemans C, Baeten M, Stang\u00e9 G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70(14):5728\u201339.","journal-title":"Cancer Res"},{"issue":"6","key":"807_CR25","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/jcmm.12787","volume":"20","author":"QH Shu","year":"2016","unstructured":"Shu QH, Ge YS, Ma HX, Gao XQ, Pan JJ, Liu D, et al. Prognostic value of polarized macrophages in patients with hepatocellular carcinoma after curative resection. J Cell Mol Med. 2016;20(6):1024\u201335.","journal-title":"J Cell Mol Med"},{"issue":"7","key":"807_CR26","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1245\/s10434-012-2263-0","volume":"19","author":"H Kurahara","year":"2012","unstructured":"Kurahara H, Takao S, Kuwahata T, Nagai T, Ding Q, Maeda K, et al. Clinical significance of folate receptor \u03b2-expressing tumor-associated macrophages in pancreatic cancer. Ann Surg Oncol. 2012;19(7):2264\u201371.","journal-title":"Ann Surg Oncol"},{"issue":"24","key":"807_CR27","doi-asserted-by":"publisher","first-page":"9395","DOI":"10.1158\/0008-5472.CAN-09-2050","volume":"69","author":"A Puig-Kr\u00f6ger","year":"2009","unstructured":"Puig-Kr\u00f6ger A, Sierra-Filardi E, Dom\u00ednguez-Soto A, Samaniego R, Corcuera MT, G\u00f3mez-Aguado F, et al. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory\/regulatory macrophages. Cancer Res. 2009;69(24):9395\u2013403.","journal-title":"Cancer Res"},{"issue":"5","key":"807_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nmeth.1318","volume":"6","author":"DG Gibson","year":"2009","unstructured":"Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA, Smith HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009;6(5):343\u20135.","journal-title":"Nat Methods"},{"issue":"4","key":"807_CR29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/mt.2015.233","volume":"24","author":"A Tedcastle","year":"2016","unstructured":"Tedcastle A, Illingworth S, Brown A, Seymour LW, Fisher KD. Actin-resistant DNAse I expression from Oncolytic adenovirus Enadenotucirev enhances its Intratumoral spread and reduces tumor growth. Mol Ther. 2016;24(4):796\u2013804.","journal-title":"Mol Ther"},{"issue":"13","key":"807_CR30","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1182\/blood-2007-02-072587","volume":"110","author":"D Duluc","year":"2007","unstructured":"Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007;110(13):4319\u201330.","journal-title":"Blood."},{"issue":"6","key":"807_CR31","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/leu.2016.35","volume":"30","author":"RC Lynn","year":"2016","unstructured":"Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS, et al. High-affinity FR\u03b2-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia. 2016;30(6):1355\u201364.","journal-title":"Leukemia."},{"issue":"7","key":"807_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00262-003-0496-2","volume":"53","author":"M Gruen","year":"2004","unstructured":"Gruen M, Bommert K, Bargou RC. T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother. 2004;53(7):625\u201332.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"807_CR33","first-page":"566","volume":"2","author":"I Matte","year":"2012","unstructured":"Matte I, Lane D, Laplante C, Rancourt C, Pich\u00e9 A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res. 2012;2(5):566\u201380.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"807_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","volume":"5","author":"R Garcia-Carbonero","year":"2017","unstructured":"Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer. 2017;5(1):71.","journal-title":"J Immunother Cancer"},{"key":"807_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.omto.2017.03.003","volume":"5","author":"S Illingworth","year":"2017","unstructured":"Illingworth S, Di Y, Bauzon M, Lei J, Duffy MR, Alvis S, et al. Preclinical safety studies of Enadenotucirev, a chimeric group B human-specific Oncolytic adenovirus. Mol Ther Oncolytics. 2017;5:62\u201374.","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"807_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","volume":"7","author":"JP Machiels","year":"2019","unstructured":"Machiels JP, Salazar R, Rottey S, Duran I, Dirix L, Geboes K, et al. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). J Immunother Cancer. 2019;7(1):20.","journal-title":"J Immunother Cancer."},{"issue":"5","key":"807_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177810","volume":"12","author":"N Marino","year":"2017","unstructured":"Marino N, Illingworth S, Kodialbail P, Patel A, Calderon H, Lear R, et al. Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. PLoS One. 2017;12(5):e0177810.","journal-title":"PLoS One"},{"issue":"3","key":"807_CR38","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","volume":"17","author":"HL Kaufman","year":"2010","unstructured":"Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718\u201330.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"807_CR39","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","volume":"106","author":"L Heinzerling","year":"2005","unstructured":"Heinzerling L, K\u00fcnzi V, Oberholzer PA, K\u00fcndig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood. 2005;106(7):2287\u201394.","journal-title":"Blood."},{"issue":"4","key":"807_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/cgt.2011.80","volume":"19","author":"TT Sahin","year":"2012","unstructured":"Sahin TT, Kasuya H, Nomura N, Shikano T, Yamamura K, Gewen T, et al. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer. Cancer Gene Ther. 2012;19(4):229\u201337.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"807_CR41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.cgt.7700066","volume":"6","author":"MJ Mastrangelo","year":"1999","unstructured":"Mastrangelo MJ, Maguire HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999;6(5):409\u201322.","journal-title":"Cancer Gene Ther"},{"issue":"suppl 4","key":"807_CR42","doi-asserted-by":"publisher","first-page":"iv368","DOI":"10.1093\/annonc\/mdu342.21","volume":"25","author":"V Boni","year":"2014","unstructured":"Boni V, Fdl P, Cubillo A, Gill-Martin M, Calvo E, Salazar R, et al. A phase 1 mechanism of action study of intra-tumoural (IT) or intravenous (IV) administration of enadenotucirev, an oncolytic Ad11\/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumour. Ann Oncol. 2014;25(suppl 4):iv368.","journal-title":"Ann Oncol"},{"issue":"1","key":"807_CR43","doi-asserted-by":"publisher","first-page":"1700187","DOI":"10.1002\/mabi.201700187","volume":"18","author":"Eleanor M. Scott","year":"2017","unstructured":"Scott EM, Duffy MR, Freedman JD, Fisher KD, Seymour LW. Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses. Macromol Biosci. 2018;18(1):1700187.","journal-title":"Macromolecular Bioscience"},{"issue":"3","key":"807_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/biomedicines4030013","volume":"4","author":"Nicholas Denton","year":"2016","unstructured":"Denton NL, Chen CY, Scott TR, Cripe TP. Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe? Biomedicines. 2016;4(3):13.","journal-title":"Biomedicines"},{"issue":"6","key":"807_CR45","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ymthe.2006.08.008","volume":"14","author":"ML Lamfers","year":"2006","unstructured":"Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B, et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther. 2006;14(6):779\u201388.","journal-title":"Mol Ther"},{"key":"807_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.omto.2018.10.001","volume":"11","author":"NL Denton","year":"2018","unstructured":"Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, et al. Myelolytic treatments enhance Oncolytic herpes Virotherapy in models of Ewing sarcoma by modulating the immune microenvironment. Mol Ther Oncolytics. 2018;11:62\u201374.","journal-title":"Mol Ther Oncolytics."},{"issue":"8","key":"807_CR47","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/ni1369","volume":"7","author":"SJ Davis","year":"2006","unstructured":"Davis SJ, van der Merwe PA. The kinetic-segregation model: TCR triggering and beyond. Nat Immunol. 2006;7(8):803\u20139.","journal-title":"Nat Immunol"},{"issue":"8","key":"807_CR48","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00262-010-0844-y","volume":"59","author":"C Bluemel","year":"2010","unstructured":"Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother. 2010;59(8):1197\u2013209.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"807_CR49","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1158\/0008-5472.CAN-06-2760","volume":"67","author":"SA Hammond","year":"2007","unstructured":"Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, et al. Selective targeting and potent control of tumor growth using an EphA2\/CD3-Bispecific single-chain antibody construct. Cancer Res. 2007;67(8):3927\u201335.","journal-title":"Cancer Res"},{"issue":"46","key":"807_CR50","doi-asserted-by":"publisher","first-page":"75339","DOI":"10.18632\/oncotarget.12180","volume":"7","author":"F Finkernagel","year":"2016","unstructured":"Finkernagel F, Reinartz S, Lieber S, Adhikary T, Wortmann A, Hoffmann N, et al. The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. Oncotarget. 2016;7(46):75339\u201352.","journal-title":"Oncotarget."},{"issue":"10","key":"807_CR51","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.4049\/jimmunol.142.10.3714","volume":"142","author":"SL Topalian","year":"1989","unstructured":"Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989;142(10):3714\u201325.","journal-title":"J Immunol"},{"issue":"13","key":"807_CR52","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-14-0433","volume":"20","author":"YC Lu","year":"2014","unstructured":"Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014;20(13):3401\u201310.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"807_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1240859","volume":"5","author":"I Poschke","year":"2016","unstructured":"Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5(12):e1240859.","journal-title":"Oncoimmunology."}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0807-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T06:19:32Z","timestamp":1695449972000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0807-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0807-6","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"12 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ascites samples were acquired with informed consent from routine drainage of cancer patients at the Churchill Hospital, Oxford, UK. Ethical approval for the study was gained from the institutional review board and research ethics committee of the Oxford Centre for Histopathology Research (Reference 09\/H0606\/5\u2009+\u20095) in accordance with the UK Human Tissue Act 2004 and the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LWS, BRC and KDF own equity or share options in PsiOxus Therapeutics (Oxford, UK), which is leading clinical development of EnAd and its derivatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"320"}}